Stockscreener 앱 받기
0.22
10.57%
-0.026
전일 마감가:
$0.246
열려 있는:
$0.252
하루 거래량:
12.99M
Relative Volume:
6.13
시가총액:
$4.95M
수익:
$7.10M
순이익/손실:
$-31.59M
주가수익비율:
-0.0843
EPS:
-2.61
순현금흐름:
$-26.75M
1주 성능:
-47.90%
1개월 성능:
-72.84%
6개월 성능:
-78.00%
1년 성능:
-88.42%
1일 변동 폭
$0.2131
$0.252
1주일 범위
$0.1605
$0.3111
52주 변동 폭
$0.1605
$2.48
Palatin Technologies Inc. Stock (PTN) Company Profile
명칭
Palatin Technologies Inc.
전화
609-495-2200
주소
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
PTN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTN
Palatin Technologies Inc.
|
0.22 | 4.95M | 7.10M | -31.59M | -26.75M | -2.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2015-06-05 | 재확인 | Canaccord Genuity | Buy |
| 2015-01-12 | 재확인 | ROTH Capital | Buy |
| 2012-05-23 | 개시 | Noble Financial | Buy |
| 2007-01-23 | 개시 | Next Generation | Buy |
Palatin Technologies Inc. 주식(PTN)의 최신 뉴스
Palatin’s obesity study shows promise in appetite control By Investing.com - Investing.com Canada
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide - The Malaysian Reserve
Dry Eye Disease Market Growth Projections 2024-2034: DelveInsight Analysis | Palatin Technologies, Novaliq, mc2 therapeutics - The Globe and Mail
Palatin (PTN) Reports Positive Phase 2 Study Results for Obesity Treatment | PTN Stock News - GuruFocus
Palatin’s obesity study shows promise in appetite control - Investing.com
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide | PTN Stock News - GuruFocus
Breakthrough Obesity Treatment Shows 71% Appetite Control, Blocks Post-Treatment Weight Rebound - Stock Titan
What Analysts Think About Palatin Technologies Inc (AMEX: PTN)’s Potential Raise - stocksregister.com
Palatin Appeals NYSE American Notice of Delisting - Kilgore News Herald
Palatin Technologies (PTN) Appeals NYSE Delisting Decision | PTN Stock News - GuruFocus
Palatin Appeals NYSE American Notice of Delisting | PTN Stock Ne - GuruFocus
Palatin Appeals NYSE Delisting, Pursues Financing And Partnerships To Regain Compliance - Nasdaq
Palatin contests NYSE American delisting notice By Investing.com - Investing.com South Africa
Palatin Appeals NYSE American Notice of Delisting | PTN Stock News - GuruFocus
Palatin contests NYSE American delisting notice - Investing.com
Palatin Appeals NYSE American Notice Of Delisting - marketscreener.com
Palatin Launches Bold Defense Against NYSE Delisting: Multi-Strategy Rescue Plan Revealed - Stock Titan
Stock Slump: Eyewear Innovator And Tech Firms Face Market Hits - Finimize
Palatin Technologies (PTN) Faces NYSE American Delisting Proceedings - GuruFocus
Palatin (PTN) Faces Delisting Proceedings from NYSE American | P - GuruFocus
Palatin to Present Positive Phase 2b Data for Melanocortin Agoni - GuruFocus
Palatin Technologies faces potential NYSE American delisting By Investing.com - Investing.com Canada
Palatin reports promising kidney disease treatment results By Investing.com - Investing.com South Africa
Palatin Technologies shares fall as it receives NYSE American delisting notice - MSN
Palatin Technologies faces potential NYSE American delisting - Investing.com Australia
Palatin Technologies, Inc. Announces Receipt Of NYSE American Notice Of Delisting And Intention To Appeal - MarketScreener
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) - Business Wire
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal - PR Newswire
Palatin reports promising kidney disease treatment results - Investing.com Australia
Palatin Technologies Reports Positive Data From Phase 2b BREAKOUT Study - Nasdaq
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting - Kilgore News Herald
Indo-Asian News Service - Indo-Asian News Service (IANS)
Palatin Technologies stock hits 52-week low at $0.45 - Investing.com
Palatin Technologies stock hits 52-week low at $0.45 By Investing.com - Investing.com India
Palatin touts Phase II obesity study results - The Pharma Letter
Palatin study shows weight loss with new drug combo By Investing.com - Investing.com Canada
Palatin Technologies’ UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data – Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN) - Barchart.com
Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight - Benzinga
Palatin study shows weight loss with new drug combo - Investing.com
Breakthrough Obesity Treatment: New Drug Combo Achieves 4.4% Weight Loss in Clinical Trial - Stock Titan
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study - The Malaysian Reserve
Palatin reported promising results in trial for ulcerative colitis treatment - MSN
PTN stock touches 52-week low at $0.67 amid market challenges - Investing.com Australia
PTN stock touches 52-week low at $0.67 amid market challenges By Investing.com - Investing.com South Africa
Palatin’s UC therapy prompts clinical remission in a third of patients - Yahoo
Palatin Technologies' Ulcerative Colitis Drug Candidate Shows Positive Results in Phase 2 Study - MarketScreener
Palatin reported promising results in trial for ulcerative colitis treatment (PTN:NYSE) - Seeking Alpha
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 - The Malaysian Reserve
Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus - Benzinga
Palatin Technologies Inc. (PTN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.51%
자본화:
|
볼륨(24시간):